ABREVA

Brand name authorized in: Canada

Active ingredients

The drug ABREVA contains one active pharmaceutical ingredient (API):

1 Docosanol
UNII 9G1OE216XY - DOCOSANOL

The exact mechanism of the antiviral activity of docosanol is unknown. In vitro studies indicate that docosanol affects the fusion between the virus and the plasma membrane, which inhibits intracellular uptake and replication of virus. Docosanol has no effect against non-enveloped viruses.

Read about Docosanol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Docosanol
D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BB Antivirals
Discover more medicines within D06BB11

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
CA
Health Products and Food Branch
Identifier(s): 02245677